By Johnson, Kate
Clinical Psychiatry News , Vol. 38, No. 12
MONTREAL -- The addition of D-cycloserine to cognitive-behavioral therapy for the treatment of posttraumatic stress disorder showed little or no benefit over placebo, based on several studies presented at the meeting.
The presentations sparked some heated debate and dampened hopes for the drug in treating posttraumatic stress disorder (PTSD), given that it has already shown promise in the treatment of social anxiety disorder, panic disorder, and some phobias - and might have potential in the treatment of obsessive-compulsive disorder and addictions.
"The early results are not as positive as we [had] hoped," commented Dr. Charles Marmar, professor and chair of the department of psychiatry at New York University, when asked to comment after the session. "We didn't see much evidence today that D-cycloserine boosts the therapeutic benefit of cognitive-behavioral therapy [CBT] in PTSD," agreed Dr. Roger Pitman, who serves as director of the Massachusetts General Hospital posttraumatic stress disorder and psychophysiology laboratory and professor of psychiatry at Harvard Medical School, both in Boston.
But Dr. Pitman cautioned against dismissing the potential of D-cycloserine (DCS) in psychiatry. "There are several published studies now in social phobia, panic disorder, and height phobia that you can't simply dismiss," he said in an interview.
"It's fair to conclude that DCS has the capability of bolstering cognitive-behavioral therapy by enhancing retention, but maybe PTSD is a tougher nut to crack."
D-cycloserine, a broad-spectrum antibiotic that has been used for decades in the treatment of tuberculosis and urinary tract infections, also is known to be a cognitive enhancer.
In animal laboratory work, DCS been shown to reduce fear in mice. Its positive effect in the treatment of human anxiety and phobia studies is believed to stem from the drug's ability to enhance learning of new responses to stressful stimuli.
"Maybe for PTSD, the neurobiological mechanisms that are associated with maintenance of this disorder are more complex than those associated with less complex disorders such as social anxiety," suggested Stephane Guay, Ph.D., director of the trauma study center at Louis-H. Lafontaine Hospital in Montreal, who presented one of the negative DCS studies at the meeting, cosponsored by Boston University.
His randomized, double-blind placebo-controlled trial included 45 adult PTSD patients, with moderate to severe symptoms. All patients received 11 or 12 sessions (duration, 90 minutes) of CBT combined with either placebo (n = 23) or DCS (n = 22) 50 mg, administered 1 hour prior to the session for sessions 4 through 11.
The idea behind administration of the drug is that cognitive-behavioral therapy is based on learning, and DCS can enhance learning, he explained. CBT was manualized, and included psychoeducation about posttraumatic stress disorder, prolonged imaginal exposure, and breathing retraining.
The main outcomes were PTSD symptoms, measured with the Clinician-Administered PTSD Scale (CAPS) and the Structured Clinical Interview for DSM-IV Disorders (SCID), and depression, measured by the Beck Depression Inventory (BDI).
Remission rates were roughly equivalent in both groups at 55% for the placebo group and 48% for the treated group immediately following the treatment, and 59% and 44% at the 6-month follow-up.
"We found that DCS didn't seem to improve or increase or accelerate the treatment," he said in an interview. …